Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next
Prostate cancer (PC) treatment is evolving beyond conventional therapies. This review explores mRNA-based vaccines as a promising immunotherapy. We discuss their mechanism of action, advantages in production and safety, and results from early clinical trials (e.g., CV9103/4). Key challenges like antigen selection and the immunosuppressive tumor microenvironment are addressed, alongside advancements in lipid nanoparticle delivery and combinatorial strategies with checkpoint inhibitors to enhance efficacy and usher in personalized PC treatment.
Authors
- Fatemeh Afrashteh (ORCID: https://orcid.org/0000-0002-3090-6175)
- Rayan Rajabi (ORCID: https://orcid.org/0000-0003-0544-4543)
- Roya Ghods (ORCID: https://orcid.org/0000-0001-5996-3758)
- Somayeh Vafaei (ORCID: https://orcid.org/0000-0002-0758-2133)
- Zahra Madjd
Institutions
- Iran University of Medical Sciences (IR)
Publication Details
- Journal
- npj Vaccines
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1038/s41541-025-01358-9
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00